The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the “inflamed tumor” to the “inflamed patient”-Reference-Cited by-同舟云学术

The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the “inflamed tumor” to the “inflamed patient”

Published:2021-01-10 Issue:7 Volume:17 Page:1930-1934
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Bersanelli Melissa¹²^ORCID,Cortellini Alessio³^ORCID,Buti Sebastiano¹^ORCID

Affiliation:

1. Medical Oncology Unit, University Hospital of Parma, Parma, Italy

2. Medicine and Surgery Department, University of Parma, Parma, Italy

3. Department of Biotechnological and Applied Clinical Sciences, St. Salvatore Hospital, University of L’Aquila, L’Aquila, Italy

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2020.1852872

Reference46 articles.

1. A comprehensive definition for metabolic syndrome

2. Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective

3. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

4. Myeloid‐derived suppressor cells and tumor: Current knowledge and future perspectives

5. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of body mass index and cholesterol‐rich apolipoprotein‐B‐containing lipoproteins on clinical outcome in NSCLC patients treated with immune checkpoint inhibitors‐based therapy: A retrospective analysis;Cancer Medicine;2024-05-31

2. Plasma proteome profiling reveals dynamic of cholesterol marker after dual blocker therapy;Nature Communications;2024-05-08

3. Diabetes and Immune Checkpoint Inhibitors—Response;Clinical Cancer Research;2023-10-02

4. Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer;Clinical Cancer Research;2023-06-01

5. Body Composition and Metabolic Dysfunction Really Matter for the Achievement of Better Outcomes in High-Grade Serous Ovarian Cancer;Cancers;2023-02-10